Inactive Instrument

Press Releases Obalon Therapeutics Inc Nasdaq

Equities

US67424L1008

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update	Apr. 01	AQ
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System	Mar. 28	AQ
ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX	Mar. 04	AQ
ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX	Feb. 22	AQ
ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX	Jan. 24	AQ
ReShape Lifesciences announces FDA PMA supplement approval for next-gen Lap-Band 2.0 Flex	Dec. 21	AQ
ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives	Dec. 20	AQ
ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX	Dec. 12	AQ
ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds	Nov. 21	AQ
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan	Nov. 08	AQ
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update	Nov. 06	AQ
ReShape Lifesciences® Announces Pricing of $3.0 Million Public Offering	23-09-29	AQ
ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI	23-09-22	AQ
ReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon System	23-09-21	AQ
ReShape Lifesciences® Significantly Strengthens Patent Portfolio Related to its Obalon® Balloon System	23-09-19	AQ
ReShape Lifesciences® Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device	23-09-14	AQ
ReShape Lifesciences® Reports Second Quarter Ended June 30, 2023 Financial Results and Provides Corporate Update	23-08-07	AQ
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2023 and Provide Corporate Update	23-08-03	AQ
ReShape Lifesciences® Signs Preferred Partner Agreement With Hive Medical for Lead Optimization Software	23-06-29	AQ
ReShape Lifesciences® Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the ASMBS 2023 Annual Meeting	23-06-28	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Obalon Therapeutics Inc Nasdaq

Equities

US67424L1008

Press Releases

Filters